The Effects of Resveratrol on Endothelial Progenitor Cells and Apoptosis Biomarkers in Postmenopausal Women with Chronic Coronary Heart Disease: A Randomized Controlled Trial

Why It Matters

Resveratrol modulates key apoptosis proteins but may impair EPC‑mediated vascular repair, prompting caution for its use in post‑menopausal coronary patients.

Key Takeaways

• Resveratrol raised anti‑apoptotic proteins Bcl‑2 and cIAP2 in participants
• Caspase‑9 levels fell significantly after 90‑day resveratrol supplementation
• Circulating CD34⁺/KDR⁺ EPCs decreased, contrary to expected endothelial benefit
• No impact observed on SIRT1, SIRT3, lipid profile, glucose, or blood pressure

Pulse Analysis

Menopause accelerates cardiovascular risk by removing estrogen’s protective effects on the endothelium, prompting researchers to explore phytoestrogens such as resveratrol. This polyphenol, abundant in grapes and berries, has demonstrated anti‑inflammatory and antioxidant properties in pre‑clinical models, often linked to activation of sirtuin pathways. However, clinical evidence on its ability to influence endothelial regeneration and apoptosis in women with established coronary disease has been limited, making the recent randomized trial a pivotal addition to the literature.

The 90‑day intervention revealed a clear biochemical shift: serum Bcl‑2 and cIAP2 rose while caspase‑9 fell, suggesting that resveratrol can dampen the intrinsic apoptosis cascade in a high‑risk population. These changes align with animal studies where enhanced anti‑apoptotic signaling protected cardiac tissue from ischemic injury. Yet the simultaneous reduction in circulating CD34⁺/KDR⁺ endothelial progenitor cells (EPCs) challenges the assumption that resveratrol uniformly supports vascular health. Possible explanations include decreased endothelial damage reducing EPC mobilization, or enhanced homing of EPCs to damaged vessels, both of which would lower peripheral counts without necessarily harming repair capacity.

For clinicians, the mixed signal underscores the need for nuanced patient selection. While resveratrol may offer anti‑apoptotic benefits, its impact on EPC dynamics could offset vascular regeneration, especially in post‑menopausal women with extensive coronary lesions. Larger, longer‑term trials should assess functional outcomes such as flow‑mediated dilation and hard cardiovascular events before recommending routine supplementation. Until then, physicians should weigh the modest biomarker improvements against the uncertain implications for endothelial repair when considering resveratrol for this demographic.